Sperm quality could be damaged by using wifi on laptops
Using a laptop to surf the internet wirelessly can significantly damage the quality of men’s sperm and even kill them, scientists are warning.
A lab study carried out by a group of researchers has found that if men use a laptop on their lap wirelessly for four hours, the wifi reduced the sperm’s mobility and damaged its DNA.
Although it has previously been suspected that using laptops can damage fertility in males, it was thought the heat generated from the machines were the problem.
To read the latest edition of Healthcare Global, click here
- Norovirus present in three quarters of UK-grown oysters
- Football headers cause brain damage in players
- Strike means thousands of operations will be cancelled
Despite the preliminary findings pointing to wifi cards as the cause of sperm damage, the scientists involved in the study have stressed more research needs to be carried out to into the matter.
They have also said if an investigation into the effect of wireless laptop use was to be carried out on humans the results presented may be entirely different to the lab-based studies.
As part of their lab research, the scientists took samples from 29 healthy sperm donors and separated them into two pots.
Their aim was to observe the impact of the electromagnetic radiation given off by laptops.
One of the sperm samples was stored next to a laptop with a live wireless internet connection and the other was stored in an identical set-up, just without the portable computer.
After a period of four hours, the sperm samples that had been most damaged were those next to the laptop – they had reduced movement and mobility and suffered significant genetic damage.
According to the news agency Reuters, 25 percent of the sperm next to the laptop had stopped moving after four hours, whereas just 14 of the other sample had no movement.
Additionally, at nine percent, the amount of sperm with DNA damage next to the laptop was three times higher than its opposing sample.
The results of the study have been published in the journal ‘Fertility and Sterility’.
Our magazine is now available on the iPad. Click here to download it.
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.